Seres Therapeutics (MCRB)
(Delayed Data from NSDQ)
$1.05 USD
0.00 (0.00%)
Updated Sep 19, 2024 03:59 PM ET
After-Market: $1.04 -0.01 (-0.95%) 7:58 PM ET
2-Buy of 5 2
F Value B Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Seres Therapeutics, Inc. [MCRB]
Reports for Purchase
Showing records 1 - 20 ( 36 total )
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 PDUFA Date Approaching and Potential Launch in Sight; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-155 Phase 1b Cohort 2 Study Enrollment Underway; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Pre-Commercialization Efforts Underway Ahead of SER-109 April 26 2023 BLA PDUFA Date; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 Edging Closer With an April 26 2023 BLA PDUFA Date; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 Rolling BLA Completed; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 BLA Weeks From Filing; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Open-Label Results Reaffirm SER-109 Safety and Efficacy; Rolling BLA Initiated
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
DE486 Potential to Reduce Chemotherapy-Induced Mucositis Inflammation; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 BLA Filing Remains on Track for Mid-2022 With Additional Positive Data; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-109 Keeps Moving Closer to the Finish Line; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Plans in the Works to Optimize Ulcerative Colitis Program; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Closer to the Finish Line and an Attractive Value Proposition; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
SER-155 Phase 1b Study Underway; Reiterate Buy and $25 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Focused Near-Term on the SER-109 Open-Label Study Reaching Target Enrollment
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Clinical Remission Not Achieved With SER-287; Lowering PT to $25 From $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Looking for SER-109 Phase 3 Success to Augur Positive Open-Label Study Results; Reiterate Buy and Raise PT to $46
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
We Remain Positive on the Emerging Microbiome-Based Approach in Treating Cancer; Reiterate Buy and $41 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Seres Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Phase 3 Success Positions SER-109 to Be a Landmark in the Microbiome Landscape; Reiterate Buy and $41 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V